WHO ICTRP trial
CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of…
NL-OMON45864 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON45864 |
|---|---|
| Public title | CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of personalized therapy |
| Scientific title | CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of personalized therapy - STAR22 study |
| Primary sponsor | Erasmus MC, Universitair Medisch Centrum Rotterdam |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 4 |
| Countries | The Netherlands |
| Conditions | cancer Neoplasm;10027656;cancer;Neoplasm |
| Interventions | Patients intended to be treated with one of the participating drugs will be prospectively genotyped for CYP3A4*22. Patients that prove to be wildtype will be treated with the standard-dose treatment. In patients homozygous or heterozygous… |
| Registration date | Jan 31, 2019 |
| Target size | 198 |
| Secondary IDs | 2018-003954-26;NL67818.078.18 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: